Revenue of pharmaceutical company Recordati 2022, by product
In 2022, total revenue of the Italian pharmaceutical group Recordati amounted to approximately 1.85 billion euros, most of which came from the production and marketing of specialty medicines. This statistic breaks down this revenue by line of products sold on the global markets. Rare diseases drugs were the category generating the largest revenues, with over 595 million euros, followed by the branded drug Zanidip, which generated revenue for around 130.5 million euros.